Background In 2008, a sharp increase of the number of children diagnosed with urinary calculi was observed in China, 9433 children were diagnosed as having melamine-induced urinary calculi at outpatient clinic in Beij...Background In 2008, a sharp increase of the number of children diagnosed with urinary calculi was observed in China, 9433 children were diagnosed as having melamine-induced urinary calculi at outpatient clinic in Beijing Children＇s Hospital. This study examined the therapeutic efficacy of potassium sodium hydrogen citrate （PSHC） used to treat melamine-induced urinary stones in Chinese children who consumed melamine-containing infant formula. Methods Seventy-two infants and children （average age （18.2±7.7） months） who were diagnosed with urinary calculi were icuidomly divided into three treatment groups using the SAS Plan program. Group 1 was given a low dose （1 g/d） of PSHC, group 2 was given high dose of PSHC （2 g/d） and group 3 was given no PSHC （control group）. The dose of drug was adjusted according to the baseline urinary pH. This study analyzed the influence of the dose of PSHC, the age of patients, stone size and position, and urinary pH on the level of efficacy of PSHC （cured, effectively treated or not cured）.Results After 1-6 months of therapy, 19 patients from group 1, five patients from group 2 and six patients from group 3 were cured. Five patients from group 1, five patients from group 2 and four patients from group 3 were effectively treated. There were significant differences in therapeutic efficacy between the two treatment doses after 3 and 6 months as measured by the increase in the successful expulsion rate and time of melamine-induced urinary calculi. After 6 months the mean time of expulsion of urinary calculi in groups 1 and 2 was significantly shorter than in the control group. Conclusions PSHC can significantly increase the successful expulsion rate and time of melamine-induced urinary calculi. The therapeutic efficacy is affected by PSHC dose, treatment duration, calculi position, and urinary pH. There is no relationship between the therapeutic efficacy and the stone size or patient age.展开更多
文摘Background In 2008, a sharp increase of the number of children diagnosed with urinary calculi was observed in China, 9433 children were diagnosed as having melamine-induced urinary calculi at outpatient clinic in Beijing Children＇s Hospital. This study examined the therapeutic efficacy of potassium sodium hydrogen citrate （PSHC） used to treat melamine-induced urinary stones in Chinese children who consumed melamine-containing infant formula. Methods Seventy-two infants and children （average age （18.2±7.7） months） who were diagnosed with urinary calculi were icuidomly divided into three treatment groups using the SAS Plan program. Group 1 was given a low dose （1 g/d） of PSHC, group 2 was given high dose of PSHC （2 g/d） and group 3 was given no PSHC （control group）. The dose of drug was adjusted according to the baseline urinary pH. This study analyzed the influence of the dose of PSHC, the age of patients, stone size and position, and urinary pH on the level of efficacy of PSHC （cured, effectively treated or not cured）.Results After 1-6 months of therapy, 19 patients from group 1, five patients from group 2 and six patients from group 3 were cured. Five patients from group 1, five patients from group 2 and four patients from group 3 were effectively treated. There were significant differences in therapeutic efficacy between the two treatment doses after 3 and 6 months as measured by the increase in the successful expulsion rate and time of melamine-induced urinary calculi. After 6 months the mean time of expulsion of urinary calculi in groups 1 and 2 was significantly shorter than in the control group. Conclusions PSHC can significantly increase the successful expulsion rate and time of melamine-induced urinary calculi. The therapeutic efficacy is affected by PSHC dose, treatment duration, calculi position, and urinary pH. There is no relationship between the therapeutic efficacy and the stone size or patient age.
